Central Pharmaceutical Joint Stock Company No3 (HNX:DP3)
52,700
+200 (0.38%)
At close: Aug 4, 2025
HNX:DP3 Balance Sheet
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Cash & Equivalents | 68,673 | 13,706 | 5,375 | 21,106 | 24,727 | 40,918 | Upgrade |
Short-Term Investments | 336,559 | 327,987 | 301,000 | 185,378 | 137,000 | 120,000 | Upgrade |
Cash & Short-Term Investments | 405,233 | 341,693 | 306,375 | 206,484 | 161,727 | 160,918 | Upgrade |
Cash Growth | 25.01% | 11.53% | 48.38% | 27.67% | 0.50% | 0.88% | Upgrade |
Accounts Receivable | 45,867 | 34,817 | 17,061 | 26,898 | 20,857 | 23,940 | Upgrade |
Other Receivables | 5,594 | 4,539 | 5,722 | 1,758 | 318.51 | 1,988 | Upgrade |
Receivables | 51,461 | 39,356 | 22,784 | 28,656 | 21,175 | 25,928 | Upgrade |
Inventory | 50,146 | 43,925 | 52,332 | 69,835 | 67,159 | 56,385 | Upgrade |
Prepaid Expenses | 463.88 | 222.42 | 247.03 | 49.57 | 334.52 | 48.83 | Upgrade |
Other Current Assets | 3,712 | 8,129 | 2,014 | 5,161 | 5,050 | 11,531 | Upgrade |
Total Current Assets | 511,016 | 433,326 | 383,752 | 310,186 | 255,446 | 254,811 | Upgrade |
Property, Plant & Equipment | 136,109 | 119,745 | 131,247 | 154,414 | 145,838 | 142,492 | Upgrade |
Other Intangible Assets | - | 20,201 | 20,281 | 6,514 | 6,594 | 5,814 | Upgrade |
Other Long-Term Assets | 34,487 | 34,504 | 35,346 | 36,755 | 37,626 | 38,242 | Upgrade |
Total Assets | 681,611 | 607,777 | 570,626 | 507,868 | 445,504 | 441,359 | Upgrade |
Accounts Payable | 6,287 | 7,642 | 15,695 | 18,474 | 19,499 | 23,880 | Upgrade |
Accrued Expenses | 66,016 | 63,340 | 59,112 | 50,742 | 44,398 | 41,568 | Upgrade |
Short-Term Debt | 19,847 | - | 6,800 | 5,230 | 3,528 | 5,378 | Upgrade |
Current Income Taxes Payable | 11,316 | 13,243 | 14,240 | 10,594 | 8,084 | 12,546 | Upgrade |
Other Current Liabilities | 67,800 | 4,671 | 5,333 | 5,378 | 3,746 | 11,539 | Upgrade |
Total Current Liabilities | 171,267 | 88,896 | 101,179 | 90,418 | 79,254 | 94,911 | Upgrade |
Long-Term Debt | - | - | 975 | - | - | - | Upgrade |
Total Liabilities | 171,267 | 88,896 | 102,154 | 90,418 | 79,254 | 94,911 | Upgrade |
Common Stock | 214,999 | 214,999 | 214,999 | 86,000 | 86,000 | 86,000 | Upgrade |
Additional Paid-In Capital | - | - | - | 97,659 | 97,659 | 97,659 | Upgrade |
Retained Earnings | 295,345 | 303,881 | 253,473 | 233,791 | 182,591 | 162,789 | Upgrade |
Shareholders' Equity | 510,344 | 518,881 | 468,472 | 417,450 | 366,250 | 346,448 | Upgrade |
Total Liabilities & Equity | 681,611 | 607,777 | 570,626 | 507,868 | 445,504 | 441,359 | Upgrade |
Total Debt | 19,847 | - | 7,775 | 5,230 | 3,528 | 5,378 | Upgrade |
Net Cash (Debt) | 385,386 | 341,693 | 298,600 | 201,254 | 158,199 | 155,540 | Upgrade |
Net Cash Growth | 18.88% | 14.43% | 48.37% | 27.21% | 1.71% | 2.97% | Upgrade |
Net Cash Per Share | 17925.61 | 15892.74 | 13888.41 | 8892.41 | 7358.34 | 7234.49 | Upgrade |
Filing Date Shares Outstanding | 21.5 | 21.5 | 21.5 | 21.5 | 21.5 | 22.63 | Upgrade |
Total Common Shares Outstanding | 21.5 | 21.5 | 21.5 | 21.5 | 21.5 | 22.63 | Upgrade |
Working Capital | 339,749 | 344,430 | 282,572 | 219,768 | 176,192 | 159,900 | Upgrade |
Book Value Per Share | 23737.02 | 24134.06 | 21789.47 | 19416.28 | 17034.87 | 15308.18 | Upgrade |
Tangible Book Value | 510,344 | 498,679 | 448,191 | 410,936 | 359,656 | 340,634 | Upgrade |
Tangible Book Value Per Share | 23737.02 | 23194.45 | 20846.14 | 19113.30 | 16728.17 | 15051.29 | Upgrade |
Buildings | - | 126,884 | 126,668 | - | - | - | Upgrade |
Machinery | - | 109,367 | 109,269 | - | - | - | Upgrade |
Construction In Progress | 120 | 120 | 401.11 | 14,390 | 5,436 | 65,364 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.